Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-journal-of-neuroradiology/off-label-use-of-drugs-and-devices-in-the-neuroendovascular-suite-y90Oi412rO
References
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
- Publisher
- American Journal of Neuroradiology
- Copyright
- Copyright © 2013 by the American Society of Neuroradiology.
- ISSN
- 0195-6108
- eISSN
- 1936-959X
- DOI
- 10.3174/ajnr.A3447
- pmid
- 23518356
- Publisher site
- See Article on Publisher Site
Abstract
SUMMARY: The off-label use of drugs and devices in neuroendovascular procedures is common. Neurointerventionalists should be well aware of the level of evidence available in support of the off-label use of drugs and devices in their practice and some of the potential adverse events associated with them. These uses are categorized as I or II if they have been evaluated as primary or ancillary interventions in prospective trials/registries of neuroendovascular procedures and III if they were evaluated in case series. Category IV use is based on evaluation as primary or ancillary interventions in prospective trials/registries of non-neuroendovascular procedures. Physicians are allowed to use off-label drugs and procedures if there is strong evidence that they are beneficial for the patient. The neurointerventional professional societies agree that off-label use of drugs and devices is an important part of the specialty, but practicing providers should base their decisions on sound evidence when using such drugs and devices. ABBREVIATIONS: GDC Guglielm i detachable coil IA intra-arterial ICH intracerebral hemorrhage PROACT Prolyse in Acute Cerebral Thromboembolism UK urokinase
Journal
American Journal of Neuroradiology – American Journal of Neuroradiology
Published: Nov 1, 2013